Scarica l'app Stockscreener
72.84
0.17%
0.12
Dopo l'orario di chiusura:
72.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$72.72
Aprire:
$72.43
Volume 24 ore:
3.69M
Relative Volume:
0.73
Capitalizzazione di mercato:
$225.83B
Reddito:
$54.07B
Utile/perdita netta:
$7.04B
Rapporto P/E:
32.30
EPS:
2.255
Flusso di cassa netto:
$7.28B
1 W Prestazione:
-4.81%
1M Prestazione:
-3.71%
6M Prestazione:
-6.16%
1 anno Prestazione:
+6.71%
Intervallo 1D:
$72.37
$73.04
Intervallo di 1 settimana:
$71.82
$75.90
Portata 52W:
$62.75
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
72.84 | 225.83B | 54.07B | 7.04B | 7.28B | 2.255 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca Fights Generic Diabetes Drug Launch - Law360
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet - Yahoo Finance
Berenberg Keeps AstraZeneca at Buy on Pipeline Potential - Marketscreener.com
Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale - Law360
J&J passes AstraZeneca in lung cancer drug race — for now - Crain's New York Business
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study - Benzinga
J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now - Bloomberg
J&J Passes AstraZeneca in Blockbuster Cancer Race — For Now - MSN
AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed - Bloomberg Law
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO - Investing.com India
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO By Investing.com - Investing.com South Africa
Europe Rapidly Falling Behind China in Pharma, AstraZeneca CEO Warns - Bloomberg
Astrazeneca invests in China: $8B in deals, $2.5B in R&D center - BioWorld Online
Astrazeneca Says Tagrisso Shows Improved Overall Survival Trend In Laura Phase 3 Trial - Marketscreener.com
AstraZeneca Seeks to Move Past China Probe With Beijing R&D Hub - Bloomberg
AstraZeneca seeks to move past China probe with Beijing R&D hub - The Edge Malaysia
AstraZeneca PLC ADR underperforms Monday when compared to competitors - MarketWatch
Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden - Yahoo Finance
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank - Proactive Investors UK
Prediction: 12 months from now, AstraZeneca’s share price could be… - Yahoo Finance UK
AstraZeneca to invest $2.5bn in R&D centre in China - Pharmaceutical Technology
Assemblin Caverion Group Unit to Upgrade AstraZeneca's Swedish Plant -March 24, 2025 at 03:37 am EDT - Marketscreener.com
Top global stories of the week: AstraZeneca, BYD, SoftBank among notable names - Seeking Alpha
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca Expands Emphasis On China, Already A Key Market - News & Insights
AstraZeneca PLC ADR falls Friday, underperforms market - MarketWatch
Sector Update: Health Care Stocks Retreat Late Afternoon -March 21, 2025 at 03:50 pm EDT - Marketscreener.com
AstraZeneca to invest $2.5bn in China after snub for UK plant - The Times
AstraZeneca To Invest $2.5B In China Research Hub - Law360
Sector Update: Health Care Stocks Fall in Afternoon Trading -March 21, 2025 at 01:50 pm EDT - Marketscreener.com
Sector Update: Health Care -March 21, 2025 at 01:39 pm EDT - Marketscreener.com
Going in vivo: AstraZeneca acquires EsoBiotec in potential $1bn deal - BioXconomy
AstraZeneca deepens China investment; Editas loses CFO to Dyne - BioPharma Dive
Kangtai Biological Products To Establish JV With AstraZeneca -March 21, 2025 at 10:40 am EDT - Marketscreener.com
AstraZeneca to invest £2bn in Beijing amid China investigation - Yahoo Finance
Micron, Johnson & Johnson, AstraZeneca: Top Stocks - Yahoo Finance
Astrazeneca enters multispecific antibody collaborations with CEPI, Harbour Biomed - BioWorld Online
AstraZeneca to make a $2.5B investment in China (AZN:NASDAQ) - Seeking Alpha
AstraZeneca invests US$2.5 bil in Beijing hub amid probe - The Edge Malaysia
AstraZeneca Expands with $2.5B Beijing R&D Hub - Investing.com
AstraZeneca expands in China with a $2.5B investment in Beijing - MSN
Syneron Bio Announces Strategic Collaboration with AstraZeneca - Yahoo Finance
AstraZeneca Invests $2.5 Billion in Beijing Hub Amid Probe - Yahoo Finance
AstraZeneca to Invest $2.5 Billion in Beijing Despite Recent Detaining of Executive -March 21, 2025 at 07:47 am EDT - Marketscreener.com
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies - The Manila Times
AstraZeneca Invests $2.5 Billion in R&D Center in China -March 21, 2025 at 07:37 am EDT - Marketscreener.com
AstraZeneca spending $2.5bn on new R&D centre, biotech deals in China - ShareCast
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals - Reuters
AstraZeneca to Set Up New $2.5 Billion R&D Center in Beijing -March 21, 2025 at 07:36 am EDT - Marketscreener.com
AstraZeneca pledges $2.5B for R&D center in Beijing - baha news
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):